In a recent paper, a member of European Food Safety Authority and Norwegian Scientific Committee for Food Safety genetically modified organism (GMO) panels has explored whether biosafety data provided to regulatory authorities by companies developing GMOs should be protected from disclosure. K.M. Nielsen, “Biosafety Data as Confidential Business Information,” PLOS Biology, 2013. Noting that standards or criteria as to what constitutes “legitimate” confidential business information (CBI) in GM product applications are lacking, the author argues that CBI claims are used indiscriminately and prevent independent research and monitoring. The article concludes with the author’s suggested criteria for “warranted CBI claims.” Among other things, the criteria would exclude from protection “information present in patent documents or for information not considered to be or not under confidentiality agreements in other companies/locations/countries.”